Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) (+) ribociclib (RIB)
Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martin M, Nusch A, Sonke GS, De La Cruz-Merino L, Beck JT, Pivot X, Sondhi M, Wang Y, Chakravartty A, Rodriguez-Lorenc K, Jerusalem G (2019)
Publication Type: Conference contribution
Publication year: 2019
Journal
Publisher: OXFORD UNIV PRESS
City/Town: OXFORD
Conference Proceedings Title: ANNALS OF ONCOLOGY
Event location: Barcelona
DOI: 10.1093/annonc/mdz394.007
Authors with CRIS profile
Involved external institutions
University of California Los Angeles (UCLA)
United States (USA) (US)
British Columbia Cancer Agency
Canada (CA)
Fondazione IRCCS: Istituto Nazionale dei Tumori
Italy (IT)
University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven
Belgium (BE)
Masaryk Memorial Cancer Institute (MMCI) / Masarykův onkologický ústav (MOÚ)
Czech Republic (CZ)
Netherlands Cancer Institute (NKI)
Netherlands (NL)
Novartis AG
Switzerland (CH)
Centre Hospitalier Universitaire de Liège (CHU Liège)
Belgium (BE)
Highlands Oncology Group
United States (USA) (US)
Seoul National University (SNU) / 서울대학교
Korea, Republic of (KR)
Hospitales Universitarios Virgen Macarena y Virgen del Rocío
Spain (ES)
NYU Langone Medical Center
United States (USA) (US)
UNICANCER Group
France (FR)
Istituto di ricovero e cura a carattere scientifico (IRCCS)
Italy (IT)
Universidad Complutense de Madrid (UCM)
Spain (ES)
United States (USA) (US)
British Columbia Cancer Agency
Canada (CA)
Fondazione IRCCS: Istituto Nazionale dei Tumori
Italy (IT)
University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven
Belgium (BE)
Masaryk Memorial Cancer Institute (MMCI) / Masarykův onkologický ústav (MOÚ)
Czech Republic (CZ)
Netherlands Cancer Institute (NKI)
Netherlands (NL)
Novartis AG
Switzerland (CH)
Centre Hospitalier Universitaire de Liège (CHU Liège)
Belgium (BE)
Highlands Oncology Group
United States (USA) (US)
Seoul National University (SNU) / 서울대학교
Korea, Republic of (KR)
Hospitales Universitarios Virgen Macarena y Virgen del Rocío
Spain (ES)
NYU Langone Medical Center
United States (USA) (US)
UNICANCER Group
France (FR)
Istituto di ricovero e cura a carattere scientifico (IRCCS)
Italy (IT)
Universidad Complutense de Madrid (UCM)
Spain (ES)
How to cite
APA:
Slamon, D.J., Neven, P., Chia, S., Fasching, P., De Laurentiis, M., Im, S.-A.,... Jerusalem, G. (2019). Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) (+) ribociclib (RIB). In ANNALS OF ONCOLOGY. Barcelona, ES: OXFORD: OXFORD UNIV PRESS.
MLA:
Slamon, D. J., et al. "Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) (+) ribociclib (RIB)." Proceedings of the 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona OXFORD: OXFORD UNIV PRESS, 2019.
BibTeX: Download